# Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer

> **NCT06591910** · — · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 50 (estimated)

## Conditions studied

- Unresectable Stage III Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Chemoimmunotherapy
- **PROCEDURE:** Surgery
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT06591910
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-20
- **Primary completion:** 2026-09-20
- **Final completion:** 2030-09-20
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06591910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06591910, "Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06591910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*